Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Summary

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Timeline

Start

2025-03-20

Primary completion

2026-05-29

Completion

2026-06-05

Outcome

Missed primary endpoint

release “The study did not meet the primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose.” evommune.com ↗

release “Phase 2b trial in adults with moderate-to-severe chronic spontaneous urticaria (CSU). The study did not meet the primary endpoint” evommune.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EVO756	Unknown	—	Oral

Indications